Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kamada, Ltd.
Collaborators
NCT07327307 · Rabies Post-exposure Prophylaxis
NCT07338786 · RabiesPrevention
NCT06998004 · Yellow Fever, Rabies
NCT07455318 · Rabies (Healthy Volunteers)
NCT07357545 · Rabies (Healthy Volunteers)
ACH
Little Rock, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions